Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

anastrozole or letrozole) following tamoxifen for 2–3 years (early 'switch' treatment) or 5 years (extended adjuvant treatment). Reducing recurrence risk is a primary goal of adjuvant hormonal ...

A couple presents after 1 year without conception despite having had sexual intercourse 2 or 3 times per week. The 36-year-old female partner has menses (lasting 3 to 5 days) every 26 to 30 days.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

Although still having a negative effect on cognition, data from the Breast International Group (BIG) 1–98 trial suggest that letrozole use ... After 2 years, 151 women were available for ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from ...

The endocrine treatment consists of either anastrozole, exemestane, letrozole, fulvestrant or ... revenues will be in the range of $1.5 million to $2.5 million and no license revenue.